CoChat

Increased Glutamine in Patients Undergoing Long-term Treatment for Schizophrenia: A Proton Magnetic Resonance Spectroscopy Study at 3 T

Open access
Bustillo, Juan R., Chen, Hongji, Jones, Thomas, Lemke, Nicholas, Abbott, Christopher, Qualls, Clifford, Canive, Jose, Gasparovic, Charles · 2014 · JAMA Psychiatry
Cited by 82

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

IMPORTANCE: The N-methyl-d-aspartic acid receptor hypofunction model of schizophrenia predicts a paradoxical increase in synaptic glutamate release. In vivo measurement of glutamatergic neurotransmission in humans is challenging, but glutamine, the principal metabolite of synaptic glutamate, can be quantified with proton magnetic resonance spectroscopy (1H-MRS). Although a few studies have measured glutamate, glutamine, and glutamine to glutamate ratio, it is not clear which of these 1H-MRS indices of glutamatergic neurotransmission is altered in schizophrenia. OBJECTIVE: To examine glutamine, glutamate, and glutamine to glutamate ratio in the dorsal anterior cingulate, as well as their relationships with symptoms and cognition in schizophrenia. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional design using 3-T 1H-MRS in participants recruited from university-based psychiatric outpatient clinics who underwent neuroimaging at an affiliated research facility. Participants were 84 patients with a DSM-IV-TR diagnosis of schizophrenia and 81 psychiatrically healthy volunteers, matched in age, sex, ethnicity, and occupational level to the head of household of family of origin. MAIN OUTCOMES AND MEASURES: Glutamine, glutamate, and glutamine to glutamate ratio. Also symptoms and cognition. RESULTS: Glutamine was increased in the schizophrenia group (P = .01) as well as the glutamine to glutamate ratio (P = .007) but not glutamate (P = .89). Glutamine levels were positively correlated with severity of psychotic symptoms (P = .02). Choline was also increased in schizophrenia (P = .002). CONCLUSIONS AND RELEVANCE: Elevated glutamine, which was directly related to psychotic symptoms, is consistent with increased glutamatergic synaptic release in schizophrenia, as predicted by the N-methyl-d-aspartic acid receptor hypofunction model. Further understanding the underlying mechanism of glutamatergic dysfunction in schizophrenia may lead to new pharmacological strategies to treat psychosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamapsychiatry.2013.3939

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 82

Metadata

Authors
Bustillo, J. R., Chen, H., Jones, T., Lemke, N., Abbott, C., Qualls, C., Canive, J., & Gasparovic, C.
Venue
JAMA Psychiatry
Published
2014-03-01
Volume
71
Issue
3
Pages
265
ISSN
2168-622X (ISSN-L)
OpenAlex
W2117774616
Cited by
82
References
14
FWCI
7.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increased Glutamine in Patients Undergoing Long-term Treatment for Schizophrenia: A Proton Magnetic Resonance Spectroscopy Study at 3 T. https://app.cochat.ai/papers/10.1001/jamapsychiatry.2013.3939
The paper
Bustillo, J. R., Chen, H., Jones, T., Lemke, N., Abbott, C., Qualls, C., Canive, J., & Gasparovic, C. (2014). Increased Glutamine in Patients Undergoing Long-term Treatment for Schizophrenia: A Proton Magnetic Resonance Spectroscopy Study at 3 T. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2013.3939

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.